Novartis Expands Radioligand Therapy Manufacturing with $200M Investment in Two US Sites

Investment Amount:
Novartis is investing $200 million to enhance its radioligand therapy manufacturing capabilities.

Locations:
The investment will fund a new site in California and the expansion of an existing site in Indianapolis.

Purpose:
The expansion aims to strengthen Novartis's radiotherapy manufacturing infrastructure, indicating a significant commitment to radioligand therapy production.

Global Context:
This investment is part of a broader trend in radiopharma financing, with other companies like Telix and ITM also securing significant funding for similar initiatives.

Previous Investments:
Novartis has previously invested in radioligand facilities, including an $85 million commitment to a production site in China.